Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.
Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.
Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
Hepatitis C treatment improves outcomes and experiences for patient and provider.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America have added updates to the hepatitis C guidelines to include kidney transplant, pregnant, and pediatric patients.
The results show no evidence to support a hypothesis of differential impact of interferon and direct-acting antiviral-based cure on risk for HCC occurrence and recurrence.
Primary care providers and nurse practitioners achieve the same sustained virologic response rates as specialists.
The prompt increased hepatitis C screening rates among baby boomers in primary care by 5-fold.
HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.
The update includes 30 new medicines for adults and 25 for children and groups antibiotics into 3 distinct categories.
Hepatitis C treatment in HIV coinfection cases is effective with standardized nurse and pharmacist support for patients in an urban clinic.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of HCV.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.
Patients with chronic HCV infection who have achieved a sustained virologic response with treatment may still be at risk for complications such as hepatocellular carcinoma.
Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.
Harvoni and Sovaldi have been approved for pediatric patients with HCV genotypes.
Regimens for the treatment of hepatitis C that included ribavirin had more mild or moderate adverse events than those without.
Drug-drug interactions are common in patients taking hepatitis C virus medications, and consulting with a pharmacist can be beneficial.
HCV infection is associated with cancers such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.
Diabetes could increase the risk of developing hepatocellular carcinoma in patients with hepatitis C.
A VA center in Wisconsin is advising veterans to be screened for hepatitis and HIV after receiving care from a dentist who did not follow VA procedures.
Treatment for 12 or 24 weeks is safe and efficacious for kidney transplant recipients with hepatitis C virus.
Researchers identified an interaction between ribavirin with paritaprevir/ritonavir/ombitasvir and dasabuvir.
The cost of the new hepatitis C drugs in low- and certain middle-income countries is rapidly declining, according to a WHO study.
Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.
The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.